Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies

about

IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer.Q56896966

P2860

Q28655505-3AB360E1-865E-4B24-8D86-FB05577A0CCF Q55367746-EB313D79-71A4-4342-B225-C25EAB854EED Q56896966-967004DC-7EB4-42FD-9FDD-7232791F0081

P2860

Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies

Item

http://www.wikidata.org/entity/Q42696006

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Epidermal growth factor recept ...... insights into target therapies

@en

Epidermal growth factor recept ...... insights into target therapies

@nl

type

Item

label

Epidermal growth factor recept ...... insights into target therapies

@en

Epidermal growth factor recept ...... insights into target therapies

@nl

prefLabel

Epidermal growth factor recept ...... insights into target therapies

@en

Epidermal growth factor recept ...... insights into target therapies

@nl

P1476

Epidermal growth factor recept ...... insights into target therapies

@en

P2093

Andrea Marin Marques

http://www.w3.org/2001/XMLSchema#string

P2860

Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Cancer treatment and survivorship statistics, 2012

Cetuximab for the treatment of colorectal cancer.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Impact of EGFR expression on colorectal cancer patient prognosis and survival.

P304

6315-6318

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3748/WJG.V19.I38.6315

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

A Araújo

Ramon Andrade de Mello

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258037480

http://www.w3.org/2001/XMLSchema#string

P698

24151349

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3801301

http://www.w3.org/2001/XMLSchema#string

Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies

about

P2860

P2860

Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932